Polygenic Risk Score Shows Promise in Predicting Future Breast Cancer in Early-Stage Patients
A new study reveals that a 313-gene polygenic risk score can predict the future risk of breast cancer in women with early-stage diagnoses, offering a promising tool for personalized treatment planning.
Recent research indicates that a blood test utilizing a polygenic risk score (PRS) based on 313 genetic markers (SNPs) can help forecast the likelihood of developing breast cancer in women diagnosed with early-stage conditions such as ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). Published in ancer Epidemiology, Biomarker & Prevention , this study analyzed data from over 2,300 women, including 2,169 with DCIS and 185 with LCIS.
The study found notable associations between PRS scores and breast cancer risk. Women with DCIS in the highest risk quartile were more than twice as likely (2.03 times) to develop cancer in the opposite breast (contralateral) compared to those in the lowest quartile. However, this score did not significantly correlate with new cancer in the same breast (ipsilateral). Conversely, among LCIS patients, higher PRS scores were linked with a greater risk of cancer in the same breast, increasing the risk by over two times.
Family history further influenced these risks, with women having a familial background of breast cancer experiencing more than a threefold increase in ipsilateral cancer risk when their PRS was high. Excluding those who underwent mastectomy and radiotherapy amplified this risk to four times.
The findings suggest that PRS can be a valuable tool in personalizing treatment plans. By integrating genetic risk scores with traditional diagnostic information, clinicians could better identify women at heightened risk who might benefit from additional preventive therapies, potentially reducing unnecessary treatments.
While promising, the researchers acknowledge limitations, such as the specific design of PRS for invasive disease rather than in-situ conditions and the relatively small cohort of LCIS cases. Further research is essential to validate these results across diverse populations and to assess additional genetic factors.
Overall, the study advances the potential of genomic tools in enhancing breast cancer risk assessment and guiding more tailored therapeutic decisions, ultimately aiming to improve patient outcomes.
source: https://medicalxpress.com/news/2025-09-polygenic-score-future-breast-cancer.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Hypertensive Disorders During Pregnancy Linked to Early Breastfeeding Difficulties and Reduced Duration
New research links hypertensive disorders during pregnancy to early breastfeeding difficulties and shorter breastfeeding duration, highlighting the need for targeted support to improve maternal and infant health outcomes.
Increased Measles Cases Reported in Michigan by Health Authorities
Michigan reports a surge in measles cases, with recent confirmed infections highlighting the ongoing public health challenge. Learn about the latest developments and importance of vaccination.
The Spread of Valley Fever in the Western U.S.: Risks to People and Dogs
Valley fever is spreading across the arid West, affecting both humans and dogs. This infectious disease caused by a soil fungus presents diagnostic challenges and severe health risks. New research and vaccines offer hope for better prevention and treatment.
AI-Powered Model Enhances Blood Sugar Management Post-Heart Surgery
A cutting-edge AI system developed by Mount Sinai enhances blood sugar control in patients recovering from heart surgery, promising safer and more personalized ICU care.